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It has been demonstrated recently that both 
CHADS2 and CHA2DS2-VASc scores have a strong 
prognostic value in predicting mainly stroke in 
patients with ACS, regardless of whether the pa-
tient had AF.11,12 Michell et al.13 enrolled 20 000 
patients with ACS without known AF in the AP-
PROACH prospective registry and showed that 
both scores predicted ischemic stroke or TIA with 
similar accuracy to that observed in historical 
populations with nonvalvular AF, but with low-
er absolute event rates. Of note, CHA2DS2-VASc 
had a higher discrimination performance than 
the CHADS2 score.
13 Podolecki et al.14 showed in 
patients with acute myocardial infarction that 
not only the risk of stroke but also of death in-
creased 4-fold in the high-risk group compared 
with the low-risk group (P < 0.001). In that study, 
every point in the CHA2DS2-VASc score was in-
dependently associated with an increase of 41% 
in stroke risk and an increase of 23% in mortali-
ty rates (P < 0.001 for both).
In the current issue of the Polish Archives of In-
ternal Medicine, Kiliszek et al.15 reports a stud y in 
which they applied both the CHA2DS2-VASc and 
modified R2CHA2DS2-VASc (additional 2 points 
for renal insufficiency, calculated estimated glo-
merular filtration rate ≤60 ml/kg/min) scores 
in patients with ACS. The assessment of renal 
function had been previously validated in the 
ROCKET-AF and ATRIA study cohorts and in-
troduced into the R2CHADS2 score.
2 Moreover, 
Barra et al.12 showed that a similarly modified 
R2CHA2DS2-VASc score has good calibration and 
high discriminative performance in the predic-
tion of ischemic stroke and all-cause mortality 
in patients after myocardial infarction.
Kiliszek et al.15 studied 2557 individuals with 
ACS who were followed up for a median of about 
5 years. The clinical data were pooled from 5 in-
dependent cardiac registries with long-term fol-
low-up. About 75% of the patients had ST-seg-
ment elevation myocardial infarction (STEMI) 
The CHA2DS2-VASc (congestive heart failure; hy-
pertension; age ≥75 years [double score]; diabe-
tes mellitus; previous stroke/transient ischemic 
attack [TIA; double score]; vascular disease; age, 
65–74 years; sex category, female) score is a val-
idated clinical prediction tool, which is currently 
used to estimate the risk of stroke in patients with 
atrial fibrillation (AF). This novel score has been 
reported to outperform the previous CHADS2 
scoring system, which despite its simplicity did 
not include many common stroke risk factors.1-3 
Therefore, even patients classified as low risk by 
CHADS2 in its original validation study had a 
stroke rate of 1.9%/year.4 In 2010, Lip et al.5 com-
pared stroke risk stratification schemes in an an-
ticoagulated AF cohort and demonstrated that 
the CHA2DS2-VASc score was characterized by 
the highest sensitivity. Additionally, the nega-
tive predictive value of this score was the high-
est among other scores with the level of about 
99.5%.5 Given the high mortality and morbidi-
ty rates associated with AF-related thromboem-
bolism, a stroke risk score that is more inclusive 
of common stroke risk factors such as CHA2DS2- 
-VASc scheme would have “flagged up” more pa-
tients for anticoagulant treatment, which would 
have the potential to reduce stroke risk in these 
individuals.6
The CHA2DS2-VASc score is a simple clinical tool 
that consists of common cardiovascular risk fac-
tors related to thromboembolism; therefore, un-
surprisingly, there have been recent reports about 
its use for prediction of stroke risk or even mortal-
ity in various cardiovascular diseases in patients 
in sinus rhythm.7,10-13 One of such cohorts are pa-
tients with acute coronary syndromes (ACS), as 
current guidelines recommend early risk stratifi-
cation to plan appropriate treatment in those pa-
tients.8-10 This can be achieved using an established 
risk scoring system that predicts mortality, such as 
GRACE or TIMI scores.10 Whether the CHA2DS2-
VASc scale can be that tool is a matter of debate.
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R2CHA2DS2-VASc scores are simple to use and easy 
to remember, they should not be a substitute for 
a more robust risk stratification tools in the eval-
uation of ACS patients. However, it is a very in-
teresting concept to use those scores as the sim-
ple and quick assessment of cardiovascular risk 
even in patients in sinus rhythm diagnosed with 
various cardiovascular diseases.
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and most of the study population was treated in-
vasively. The aim of the investigators was to assess 
the long-term predictive value of CHA2DS2-VASc 
and R2CHA2DS2-VASc scores in ACS patients with-
out a history of AF and to compare those scales 
with the TIMI and GRACE scores.
The investigators showed that both the 
CHA2DS2-VASc and R2CHA2DS2-VASc scores were 
strongly significant predictors of total mortali-
ty. After correction for heart rate on admission, 
systolic blood pressure on admission, previous 
myocardial infarction and left ventricular ejec-
tion fraction, the scores were still significantly 
predictive of mortality. The Kaplan–Meier curves 
showed a gradually worsening prognosis as the 
R2CHA2DS2-VASc score increased.
Kiliszek et al.15 also compared the CHA2DS2- 
-VASc and R2CHA2DS2-VASc scores to the wide-
ly used in myocardial infarction GRACE, TIMI 
STEMI, and TIMI NSTEMI risk scores in terms 
of predicting mortality in the analyzed popula-
tion. They found that the GRACE and TIMI STEMI 
scores were superior to the CHA2DS2-VASc and 
R2CHA2DS2-VASc scores, which was not surpris-
ing. However, when the GRACE score was com-
pared with R2CHA2DS2-VASc the difference was 
significant only at 1-year follow-up. Moreover, 
the TIMI NSTEMI score was not different from 
the CHA2DS2-VASc score and even worse than the 
R2CHA2DS2-VASc score. Of note, the R2CHA2DS2- 
-VASc score presented better predictive values 
than the CHA2DS2-VASc score. The most potent 
factors influencing mortality were age, chron-
ic kidney disease, and previous stroke. An inter-
esting observation of a “protective” effect of fe-
male sex in the multivariate analysis clearly re-
quires further studies.
The results of Kiliszek et al.15 are similar to 
those reported by previous studies in patients 
with ACS. The major difference between those 
studies is the type of the study population. Con-
trary to previous studies, Kiliszek et al.15 enrolled 
most of the patients with STEMI who were treat-
ed invasively with primary percutaneous coro-
nary intervention. Therefore, the observations 
were made in a contemporary population of ACS 
patients treated according to the current guide-
lines. Moreover, a major advantage of the anal-
ysis was the comparison of CHA2DS2-VASc and 
R2CHA2DS2-VASc with the accepted and widely 
used GRACE and TIMI scores. Last but not least, 
it was the largest cohort of patients with ACS 
studied with a long-term follow-up.
In summary, the CHA2DS2-VASc and R2CHA2- 
DS2-VASc scores can predict mortality risk in pa-
tients with ACS who are in sinus rhythm. These 
scores are much easier to apply compared with the 
recommended and widely used GRACE or TIMI 
scores; therefore, they can be calculated directly 
at the bedside. The GRACE or TIMI risk score is 
more complicated and requires the user to input 
various risk factors into a special formula (which 
can be done online), where the estimated risk 
is calculated. Although the CHA2DS2-VASc and 
